这已不是白云山旗下公司首次被曝出违规行为。2022年,国家医保局曾通报,白云山旗下三家公司涉嫌药品虚高定价、套取资金。去年下半年,白云山前董事长李楚源因涉嫌严重违纪违法,接受广东省纪委监委纪律审查和监察调查。与之相对应的是白云山居高不下的销售费用。2021年至2023年间白云山销售费用分别高达59.55亿元、58.75亿元、61.05亿元。7家药企涉销售违规从7家药企的致歉声明来看,所涉事项均为...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.